SCHEMBL264072

SCHEMBL264072

O=C1CCc2cccc(O)c2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.53
BAD Q92934 1/20 0.53
CYP2A6 P11509 1/20 0.52
DRD2 P14416 2/20 0.50
DRD3 P35462 2/20 0.50
DRD1 P21728 1/20 0.50
DRD5 P21918 1/20 0.50
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPN P05981 1/20 0.47
CYP3A4 P08684 1/20 0.47
ALOX5 P09917 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
PTGS1 P23219 1/20 0.47
PDE4A P27815 1/20 0.47
KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266203 0.84 BCL2L1 (0.53) BCL2L1BADCYP2A6DRD2DRD3
SCHEMBL25300354 0.83 CYP1A2 (0.52) BCL2L1BADCYP2A6DRD2DRD3
SCHEMBL29414699 0.78
SCHEMBL150017 0.78
SCHEMBL5535806 0.78 CYP2A6 (0.54) BCL2L1BADCYP2A6MEN1USP2
Formaldehyde SCHEMBL17491106 0.77 BCL2L1 (0.65) BCL2L1BADDRD2DRD3DRD1
SCHEMBL5836173 0.76 CYP2A6 (0.52) CYP2A6CYP1A2
SCHEMBL1871985 0.76 CYP2A6 (0.52) CYP2A6DRD2DRD3MEN1KMT2A
SCHEMBL206466 0.76 CYP2A6 (0.52) CYP2A6MEN1ALDH1A1CYP3A4MAPT
SCHEMBL12430512 0.76 CYP2A6 (0.52) BCL2L1BADCYP2A6MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431378-B2 Aminotransferase, gene encoding the same, and methods of using them KANEKA CORPORATION (JP) 2013-04-30 US disclosed
US-20120164724-A1 NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM KANEKA CORPORATION (JP) 2012-06-28 US disclosed
US-8133705-B2 Aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2012-03-13 US disclosed
US-8101638-B2 6-substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2012-01-24 US disclosed
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2010-11-11 US disclosed
US-20100105915-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2010-04-29 US disclosed
WO-2010003475-A2 NOVEL PYRROLIDONE DERIVATIVES FOR USE AS METAP-2 INHIBITORS MERCK PATENT GMBH (DE) 2010-01-14 WO disclosed
US-7629337-B2 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION (US) 2009-12-08 US disclosed
EP-1889907-B1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME KANEKA CORP (JP) 2009-09-02 EP disclosed
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PEDREGAL-TERCERO CONCEPCION 2009-01-22 US disclosed
US-6750348-B1 PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE ANORMED, INC. (CA) 2004-06-15 US disclosed
CN-1351601-A Heterocyclic compounds binding chemotactic factor receptor ANORMED INC (CA) 2002-05-29 CN disclosed
EP-1163238-A1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2001-12-19 EP disclosed
WO-2000056729-A1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2000-09-28 WO disclosed
EP-0640618-B1 Tetrahydronaphthalene-peptide derivatives HOFFMANN LA ROCHE (CH) 1999-10-20 EP disclosed
US-5837807-A DIPEPTIDES AND CYCLIC PEPTIDE DERIVATIVES OF AMINO TETRAHYDRONAPHTHALENECARBOXYLIC ACID AND HELICAL DOMAINS HOFFMANN-LA ROCHE INC. (US) 1998-11-17 US disclosed
US-5644024-A MIMICS OF PEPTIDE DOMAINS, SEQUENCE DETERMINATION, DRUGS HOFFMANN-LA ROCHE INC. (US) 1997-07-01 US disclosed
EP-0729972-A1 Peptide derivatives of tetrahydronaphthalene F. HOFFMANN-LA ROCHE AG (CH) 1996-09-04 EP disclosed
EP-0640618-A1 Tetrahydronaphthalene-peptide derivatives F. HOFFMANN-LA ROCHE AG (CH) 1995-03-01 EP disclosed
US-5164385-A AZETIDINE DERIVATIVES AND HYPOTENSIVE COMPOSITIONS THEREOF JOHN WYETH & BROTHER, LTD. (GB) 1992-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105915-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS CXCR4, CCR5, CXCR3 BCL2L1 1263/4885BAD 128/4885CYP2A6 3709/4885
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS OPRM1, OPRK1, OPRD1 BCL2L1 4772/4885BAD 3044/4885CYP2A6 210/4885
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them BCAT1, AGXT, ALDH7A1 BCL2L1 3951/4885BAD 3882/4885CYP2A6 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.